Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma.

Segawa, Takuya; Motoshima, Takanobu; Yatsuda, Junji; Kurahashi, Ryoma; Fukushima, Yumi; Murakami, Yoji; Yamaguchi, Takahiro; Sugiyama, Yutaka; Yoshida, Ryoji; Nakayama, Hideki; Kamba, Tomomi

Segawa, Takuya; Motoshima, Takanobu; Yatsuda, Junji; Kurahashi, Ryoma; Fukushima, Yumi; Murakami, Yoji; Yamaguchi, Takahiro; Sugiyama, Yutaka; Yoshida, Ryoji; Nakayama, Hideki; Kamba, Tomomi.

Afiliação

Segawa T; Department of Urology Kumamoto University Kumamoto Japan.
Motoshima T; Department of Urology Kumamoto University Kumamoto Japan.
Yatsuda J; Department of Urology Kumamoto University Kumamoto Japan.
Kurahashi R; Department of Urology Kumamoto University Kumamoto Japan.
Fukushima Y; Department of Urology Kumamoto University Kumamoto Japan.
Murakami Y; Department of Urology Kumamoto University Kumamoto Japan.
Yamaguchi T; Department of Urology Kumamoto University Kumamoto Japan.
Sugiyama Y; Department of Urology Kumamoto University Kumamoto Japan.
Yoshida R; Department of Oral and Maxillofacial Surgery Kumamoto University Kumamoto Japan.
Nakayama H; Department of Oral and Maxillofacial Surgery Kumamoto University Kumamoto Japan.
Kamba T; Department of Urology Kumamoto University Kumamoto Japan.

IJU Case Rep ; 6(2): 147-149, 2023 Mar.

Article em En | MEDLINE | ID: mdl-36874997

Palavras-chave

immune checkpoint inhibitor; immunerelated adverse event; pilocarpine; sicca syndrome; xerostomia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IJU Case Rep Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IJU Case Rep Ano de publicação: 2023 Tipo de documento: Article